Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab the company’s third distinct checkpoint inhibitor in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma First disclosure of results from CheckMate -648 demonstrate Opdivo plus Yervoy and Opdivo plus chemotherapy’s potential to address unmet needs in ...
Source: investingnews.com